

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Volume 51

July 2007

No. 7

MECHANISMS OF ACTION: PHYSIOLOGICAL EFFECTS

- Transcriptional Response of *Candida parapsilosis* following Exposure to Farnesol** Tristan Rossignol, Mary E. Logue, Kieran Reynolds, Muriel Grenon, Noel F. Lowndes, and Geraldine Butler 2304–2312
- Amiodarone and Bepridil Inhibit Anthrax Toxin Entry into Host Cells** Ana M. Sanchez, Diane Thomas, Eugene J. Gillespie, Robert Damoiseaux, Joseph Rogers, Jonathan P. Saxe, Jing Huang, Marianne Manchester, and Kenneth A. Bradley 2403–2411
- Modular Structure of Microcin H47 and Colicin V** María F. Azpiroz and Magela Laviña 2412–2419
- Inhibition of Isolated *Mycobacterium tuberculosis* Fatty Acid Synthase I by Pyrazinamide Analogs** Silvana C. Ngo, Oren Zimhony, Woo Jin Chung, Halimah Sayahi, William R. Jacobs, Jr., and John T. Welch 2430–2435
- Dual Targeting of DNA Gyrase and Topoisomerase IV: Target Interactions of Heteroaryl Isothiazolones in *Staphylococcus aureus*** Jijun Cheng, Jane A. Thanassi, Christy L. Thoma, Barton J. Bradbury, Milind Deshpande, and Michael J. Pucci 2445–2453
- Mass Spectrometry-Based Systems Approach for Identification of Inhibitors of *Plasmodium falciparum* Fatty Acid Synthase** Shilpi Sharma, Shailendra Kumar Sharma, Rahul Modak, Krishanpal Karmodiya, Namita Surolia, and Avadheshia Surolia 2552–2558
- Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of *Escherichia coli*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Streptococcus pneumoniae*** Todd A. Davies, Malcolm G. P. Page, Wenchi Shang, Ted Andrew, Malgosia Kania, and Karen Bush 2621–2624

MECHANISMS OF RESISTANCE

- Multicopy *bla*_{OXA-58} Gene as a Source of High-Level Resistance to Carbapenems in *Acinetobacter baumannii*** Alessia Bertini, Laurent Poiré, Sandrine Bernabeu, Daniela Fortini, Laura Villa, Patrice Nordmann, and Alessandra Carattoli 2324–2328
- Biochemical Characterization of PER-2 and Genetic Environment of *bla*_{PER-2}** Pablo Power, José Di Conza, María Margarita Rodríguez, Bárbara Ghiglione, Juan A. Ayala, José María Casellas, Marcela Radice, and Gabriel Gutkind 2359–2365
- Role for Cell Density in Antifungal Drug Resistance in *Candida albicans* Biofilms** Palani Perumal, Satish Mekala, and W. LaJean Chaffin 2454–2463
- Transferable Resistance to Aminoglycosides by Methylation of G1405 in 16S rRNA and to Hydrophilic Fluoroquinolones by QepA-Mediated Efflux in *Escherichia coli*** Bruno Périchon, Patrice Courvalin, and Marc Galimand 2464–2469
- High-Level Gentamicin Resistance Mediated by a Tn4001-Like Transposon in Seven Nonclonal Hospital Isolates of *Streptococcus pasteurianus*** Viola C. Y. Chow, Peter M. Hawkey, Edward W. C. Chan, Miu L. Chin, T. K. Au, Danny K. C. Fung, and Raphael C. Y. Chan 2508–2513

Continued on following page

| | | |
|---|--|-----------|
| Identification and Phenotypic Characterization of a β-Lactam-Dependent, Methicillin-Resistant <i>Staphylococcus aureus</i> Strain | Fred Goldstein, Jiri Perutka, Arabela Cuirolo, Konrad Plata, Diego Faccione, Joanne Morris, Aude Sournia, Marie Dominique Kitzis, Aicha Ly, Gordon Archer, and Adriana E. Rosato | 2514–2522 |
| Ampicillin-Resistant Non-β-Lactamase-Producing <i>Haemophilus influenzae</i> in Spain: Recent Emergence of Clonal Isolates with Increased Resistance to Cefotaxime and Cefixime | Silvia García-Cobos, José Campos, Edurne Lázaro, Federico Román, Emilia Cercenado, César García-Rey, María Pérez-Vázquez, Jesús Oteo, and Francisco de Abajo | 2564–2573 |
| <i>gyrA</i> and <i>parC</i> Mutations and Associated Quinolone Resistance in <i>Vibrio anguillarum</i> Serotype O2b Strains Isolated from Farmed Atlantic Cod (<i>Gadus morhua</i>) in Norway | D. J. Colquhoun, L. Aarflot, and C. F. Melvold | 2597–2599 |
| Characterization of an Integron Carrying <i>bla</i>_{IMP-1} and a New Aminoglycoside Resistance Gene, <i>aac</i>(6')-3I, and Its Dissemination among Genetically Unrelated Clinical Isolates in a Brazilian Hospital | Rodrigo E. Mendes, Mariana Castanheira, Mark A. Toleman, Helio S. Sader, Ronald N. Jones, and Timothy R. Walsh | 2611–2614 |
| Association between <i>embB</i> Codon 306 Mutations and Drug Resistance in <i>Mycobacterium tuberculosis</i> | Xin Shen, Guo-miao Shen, Jie Wu, Xiao-hong Gui, Xia Li, Jian Mei, Kathryn DeRiemer, and Qian Gao | 2618–2620 |
| Prevalence, Characteristics, and Molecular Epidemiology of Macrolide and Fluoroquinolone Resistance in Clinical Isolates of <i>Streptococcus pneumoniae</i> at Five Tertiary-Care Hospitals in Korea | Jeong Hwan Shin, Hee Jung Jung, Hye Ran Kim, Joseph Jeong, Seok Hoon Jeong, Sunjoo Kim, Eun Yup Lee, Jeong Nyeo Lee, and Chulhun Ludgerus Chang | 2625–2627 |
| <i>bla</i>_{VIM-2}-Harboring Integrons Isolated in India, Russia, and the United States Arise from an Ancestral Class 1 Integron Predating the Formation of the 3' Conserved Sequence | Mark A. Toleman, Hemalatha Vinodh, Uma Sekar, Vijaylakshmi Kamat, and Timothy R. Walsh | 2636–2638 |
| SUSCEPTIBILITY | | |
| Antiplasmodial Activity of Aryltetralone Lignans from <i>Holostylis reniformis</i> | Valter F. de Andrade-Neto, Tito da Silva, Lucia M. Xavier Lopes, Virgílio E. do Rosário, Fernando de Pilla Varotti, and Antoniana U. Krettli | 2346–2350 |
| In Vitro Susceptibility of <i>Sporothrix schenckii</i> to Six Antifungal Agents Determined Using Three Different Methods | Eidi Alvarado-Ramírez and Josep M. Torres-Rodríguez | 2420–2423 |
| In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents | Nikolaos G. Almyroudis, Deanna A. Sutton, Annette W. Fothergill, Michael G. Rinaldi, and Shimon Kusne | 2587–2590 |
| In Vitro Activities of CG400549, a Novel FabI Inhibitor, against Recently Isolated Clinical Staphylococcal Strains in Korea | Jong Hwa Yum, Chang Ki Kim, Dongeun Yong, Kyungwon Lee, Yunsop Chong, Cheol Min Kim, Jeong Mi Kim, Seonggu Ro, and Joong Myung Cho | 2591–2593 |

BIOLOGIC RESPONSE MODIFIERS

AM3 Modulates Dendritic Cell Pathogen Recognition Capabilities by Targeting DC-SIGN

Diego Serrano-Gómez, Rocío T. Martínez-Nuñez, Elena Sierra-Filardi, Nuria Izquierdo, María Colmenares, Jesús Pla, Luis Rivas, Javier Martínez-Picado, Jesús Jimenez-Barbero, José Luis Alonso-Lebrero, Salvador González, and Angel L. Corbí 2313–2323

ANALYTICAL PROCEDURES

Statistical Methods for Establishing Quality Control Ranges for Antibacterial Agents in Clinical and Laboratory Standards Institute Susceptibility Testing

John Turnidge and Gerry Bordash 2483–2488

ANTIVIRAL AGENTS

The L80I Substitution in the Reverse Transcriptase Domain of the Hepatitis B Virus Polymerase Is Associated with Lamivudine Resistance and Enhanced Viral Replication In Vitro

Nadia Warner, Stephen Locarnini, Michael Kuiper, Angeline Bartholomeusz, Anna Ayres, Lilly Yuen, and Tim Shaw 2285–2292

Nonnucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity

Laura K. White, Jeong-Joong Yoon, Jin K. Lee, Aiming Sun, Yuhong Du, Haian Fu, James P. Snyder, and Richard K. Plemper 2293–2303

Heparin-Mimicking Sulfonic Acid Polymers as Multitarget Inhibitors of Human Immunodeficiency Virus Type 1 Tat and gp120 Proteins

Antonella Bugatti, Chiara Urbinati, Cosetta Ravelli, Erik De Clercq, Sandra Liekens, and Marco Rusnati 2337–2345

Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects

Nimalie D. Stone, Shelia B. Dunaway, Charles Flexner, Camlin Tierney, Gary B. Calandra, Stephen Becker, Ying-Jun Cao, Ilene P. Wiggins, Jeanne Conley, Ron T. MacFarland, Jeong-Gun Park, Christina Lalama, Sally Snyder, Beatrice Kallungal, Karin L. Klingman, and Craig W. Hendrix 2351–2358

A Novel Fluorescence Intensity Screening Assay Identifies New Low-Molecular-Weight Inhibitors of the gp41 Coiled-Coil Domain of Human Immunodeficiency Virus Type 1

Lifeng Cai and Miriam Gochin 2388–2395

Defining Limits of Treatment with Humanized Neutralizing Monoclonal Antibody for West Nile Virus Neurological Infection in a Hamster Model

John D. Morrey, Venkatraman Siddharthan, Aaron L. Olsen, Hong Wang, Justin G. Julander, Jeffery O. Hall, Hua Li, Jeffrey L. Nordstrom, Scott Koenig, Syd Johnson, and Michael S. Diamond 2396–2402

In Vitro Resistance Selection and In Vivo Efficacy of Morpholino Oligomers against West Nile Virus

Tia S. Deas, Corey J. Bennett, Susan A. Jones, Mark Tilgner, Ping Ren, Melissa J. Behr, David A. Stein, Patrick L. Iversen, Laura D. Kramer, Kristen A. Bernard, and Pei-Yong Shi 2470–2482

Rapamycin Reduces CCR5 Density Levels on CD4 T Cells, and This Effect Results in Potentiation of Enfuvirtide (T-20) against R5 Strains of Human Immunodeficiency Virus Type 1 In Vitro

Alonso Heredia, Bruce Gilliam, Olga Latinovic, Nhut Le, Douty Bamba, Anthony DeVico, Gregory B. Melikyan, Robert C. Gallo, and Robert R. Redfield 2489–2496

| | | |
|---|---|-----------|
| Strong and Selective Inhibitors of Hepatitis B Virus Replication among Novel N⁴-Hydroxy- and 5-Methyl-β-L-Deoxycytidine Analogues | E. Matthes, A. Funk, I. Krahn, K. Gaertner, M. von Janta-Lipinski, L. Lin, H. Will, and H. Sirma | 2523–2530 |
| Absence of a Universal Mechanism of Mitochondrial Toxicity by Nucleoside Analogs | Kaleb C. Lund, LaRae L. Peterson, and Kendall B. Wallace | 2531–2539 |
| Selective Inhibition of Porcine Endogenous Retrovirus Replication in Human Cells by Acyclic Nucleoside Phosphonates | Minyi Shi, Xin Wang, Erik De Clercq, Sonshin Takao, and Masanori Baba | 2600–2604 |
| Neutralizing Viruses in Suspensions by Copper Oxide-Based Filters | Gadi Borkow, Robert W. Sidwell, Donald F. Smee, Dale L. Barnard, John D. Morrey, Humberto H. Lara-Villegas, Yonat Shemer-Avni, and Jeffrey Gabbay | 2605–2607 |
| Safety and Activity of the Immune Modulator HE2000 on the Incidence of Tuberculosis and Other Opportunistic Infections in AIDS Patients | Dwight R. Stickney, Zoja Noveljic, Armando Garsd, Daniel A. Destiche, and James M. Frincke | 2639–2641 |
| Sultam Thiourea Inhibition of West Nile Virus | Eric Barklis, Amelia Still, Mohammad I. Sabri, Alec J. Hirsch, Janko Nikolich-Zugich, James Brien, Tenzin Choesang Dhenub, Isabel Scholz, and Ayna Alfadhli | 2642–2645 |

EXPERIMENTAL THERAPEUTICS

| | | |
|--|---|-----------|
| Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate <i>Staphylococcus aureus</i> | José M. Miró, Cristina García-de-la-Mària, Yolanda Armero, Elisa de-Lazzari, Dolors Soy, Asunción Moreno, Ana del Rio, Manel Almela, Carlos A. Mestres, José M. Gatell, María-Teresa Jiménez-de-Anta, Francesc Marco, and the Hospital Clínic Experimental Endocarditis Study Group | 2373–2377 |
| Efficacy of a Novel Rifamycin Derivative, ABI-0043, against <i>Staphylococcus aureus</i> in an Experimental Model of Foreign-Body Infection | Andrej Trampuz, Christopher K. Murphy, David M. Rothstein, Andreas F. Widmer, Regine Landmann, and Werner Zimmerli | 2540–2545 |
| Influence of High Mutation Rates on the Mechanisms and Dynamics of In Vitro and In Vivo Resistance Development to Single or Combined Antipseudomonal Agents | V. Plasencia, N. Borrell, M. D. Maciá, B. Moya, J. L. Pérez, and A. Oliver | 2574–2581 |
| RNAIII-Inhibiting-Peptide-Loaded Polymethylmethacrylate Prevents In Vivo <i>Staphylococcus aureus</i> Biofilm Formation | Paloma Anguita-Alonso, Andrea Giacometti, Oscar Cirioni, Roberto Ghiselli, Fiorenza Orlando, Vittorio Saba, Giorgio Scalise, Milica Sevo, Marina Tuzova, Robin Patel, and Naomi Balaban | 2594–2596 |
| Combined Therapies in a Murine Model of Blastoschizomycosis | Carolina Serena, M. Mar Rodríguez, Marçal Mariné, F. Javier Pastor, and Josep Guarro | 2608–2610 |
| Efficacy of Fluoroquinolones against <i>Leptospira interrogans</i> in a Hamster Model | Matthew E. Griffith, James E. Moon, Erica N. Johnson, Kyra P. Clark, Joshua S. Hawley, Duane R. Hospenthal, and Clinton K. Murray | 2615–2617 |
| Inhibition of Type III Secretion in <i>Salmonella enterica</i> Serovar Typhimurium by Small-Molecule Inhibitors | Debra L. Hudson, Abigail N. Layton, Terry R. Field, Alison J. Bowen, Hans Wolf-Watz, Mikael Elofsson, Mark P. Stevens, and Edouard E. Galyov | 2631–2635 |

| | | |
|--|--|-----------|
| Lack of an Effect of Antibiotic Treatment on Prolonged Detection of Chlamydial DNA in Murine Genital Tract Infection | Dawn M. Reeves, Uma Nagarajan, Catherine O'Connell, Charles W. Andrews, Jr., and Toni Darville | 2646–2648 |
| CLINICAL THERAPEUTICS | | |
| <i>Enterobacteriaceae</i> Bloodstream Infections: Presence of Integrons, Risk Factors, and Outcome | George L. Daikos, Chris Kosmidis, Panayotis T. Tassios, George Petrikkos, Alexandra Vasilakopoulou, Mina Psychogiou, Ioanna Stefanou, Athina Avlami, and Nikolaos Katsilambros | 2366–2372 |
| Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers | J. B. Bulitta, S. B. Duffull, M. Kinzig-Schippers, U. Holzgrabe, U. Stephan, G. L. Drusano, and F. Sörgel | 2497–2507 |
| Pharmacokinetics and Tolerability of a Higher Rifampin Dose versus the Standard Dose in Pulmonary Tuberculosis Patients | Rovina Ruslami, Hanneke M. J. Nijland, Bacht Alisjahbana, Ida Parwati, Reinout van Crevel, and Rob E. Aarnoutse | 2546–2551 |
| Comparative Study of the Effects of Pyridoxine, Rifampin, and Renal Function on Hematological Adverse Events Induced by Linezolid | Alex Soriano, Mar Ortega, Sebastián García, Georgina Peñarroja, Albert Bové, Miguel Marcos, Juan C. Martínez, José A. Martínez, and Josep Mensa | 2559–2563 |
| Vancomycin In Vitro Bactericidal Activity and Its Relationship to Efficacy in Clearance of Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia | Pamela A. Moise, George Sakoulas, Alan Forrest, and Jerome J. Schentag | 2582–2586 |
| Prospective Randomized Trial of Empiric Therapy with Trimethoprim-Sulfamethoxazole or Doxycycline for Outpatient Skin and Soft Tissue Infections in an Area of High Prevalence of Methicillin-Resistant <i>Staphylococcus aureus</i> | Mary Jo Cenizal, Daniel Skiest, Samuel Lubner, Roger Bedimo, Pat Davis, Patrick Fox, Kathleen Delaney, and R. Doug Hardy | 2628–2630 |
| PHARMACOLOGY | | |
| Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic Populations | Tawanda Gumbo, Arnold Louie, Weiguo Liu, David Brown, Paul G. Ambrose, Sujata M. Bhavnani, and George L. Drusano | 2329–2336 |
| Probability of Target Attainment for Ceftobiprole as Derived from a Population Pharmacokinetic Analysis of 150 Subjects | Thomas P. Lodise, Jr., Rien Pypstra, James B. Kahn, Bindu P. Murthy, Hui C. Kimko, Karen Bush, Gary J. Noel, and George L. Drusano | 2378–2387 |
| Pharmacokinetics of the Anti-Human Immunodeficiency Virus Agent 1-(β -D-Dioxolane)Thymine in Rhesus Monkeys | Ghazia Asif, Selwyn J. Hurwitz, Aleksandr Obikhod, David Delinsky, Janarthanan Narayanasamy, Chung K. Chu, Harold M. McClure, and Raymond F. Schinazi | 2424–2429 |
| Steady-State Disposition of the Nonpeptidic Protease Inhibitor Tipranavir when Coadministered with Ritonavir | Linzhì Chen, John P. Sabo, Elsy Philip, Yanping Mao, Stephen H. Norris, Thomas R. MacGregor, Jan M. Wruck, Sandra Garfinkel, Mark Castles, Amy Brinkman, and Hernan Valdez | 2436–2444 |

**RECENT U.S. FOOD AND DRUG ADMINISTRATION
APPROVALS**

**New Antimicrobial Agents Approved by the U.S. Food and
Drug Administration in 2006 and New Indications for
Previously Approved Agents**

2649

LETTERS TO THE EDITOR

***Vibrio splendidus* as the Source of Plasmid-Mediated QnrS-
Like Quinolone Resistance Determinants**

Vincent Cattoir, Laurent Poirel,
Didier Mazel, Claude-James Soussy,
and Patrice Nordmann

2650–2651

**Plasmid-Mediated Quinolone Resistance Determinant
QnrB4 Identified in France in an *Enterobacter cloacae*
Clinical Isolate Coexpressing a QnrS1 Determinant**

Vincent Cattoir, Laurent Poirel, and
Patrice Nordmann

2652–2653

**Atorvastatin Is 10-Fold More Active In Vitro than Other
Statins against *Plasmodium falciparum***

Bruno Pradines, Marylin
Torrentino-Madamet, Albin
Fontaine, Maud Henry, Eric Baret,
Joel Mosnier, Sébastien Briolant,
Thierry Fusai, and Christophe
Rogier

2654–2655

**Relationship of Blood Level and Susceptibility in
Voriconazole Treatment of Histoplasmosis**

Alison Freifeld, Sandra Arnold,
Winnie Ooi, Fabian Chen, Thomas
Meyer, L. Joseph Wheat, Melinda
Smedema, Ann Lemonte, and
Patricia Connolly

2656–2657

Genetic Environment of ISEcp1 and *bla*_{ACC-1}

Letter: Sally R. Partridge. *Reply:*
Guillaume Arlet

2658–2659